Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
出版年份 2016 全文链接
标题
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
作者
关键词
Meta-analysis, Serum electrolytes, Serum magnesium, SGLT2 inhibitors, Type 2 diabetes
出版物
DIABETOLOGIA
Volume 59, Issue 12, Pages 2546-2551
出版商
Springer Nature
发表日期
2016-09-15
DOI
10.1007/s00125-016-4101-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effects of Magnesium Supplementation on Blood PressureNovelty and Significance
- (2016) Xi Zhang et al. HYPERTENSION
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Serum Magnesium and Mortality in Hemodialysis Patients in the United States: A Cohort Study
- (2015) Eduardo Lacson et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
- (2015) Andrew Lewin et al. DIABETES CARE
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- (2015) Ralph A. DeFronzo et al. DIABETES CARE
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
- (2015) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
- (2015) Hans-Ulrich Haering et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Hypermagnesemia is a strong independent risk factor for mortality in critically ill patients: Results from a cross-sectional study
- (2015) Dominik G. Haider et al. European Journal of Internal Medicine
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial
- (2015) Chieh-Hsiang Lu et al. Journal of Diabetes Investigation
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
- (2014) Matthew R. Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
- (2014) Julio Rosenstock et al. DIABETES CARE
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
- (2014) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial
- (2014) C. J. Bailey et al. DIABETIC MEDICINE
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies
- (2013) Liana C Del Gobbo et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
- (2013) J. P. H. Wilding et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- Hypermagnesemia Predicts Mortality in Elderly with Congestive Heart Disease: Relationship with Laxative and Antacid Use
- (2008) Graziamaria Corbi et al. REJUVENATION RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started